Shantel A Vital1, Felix Becker1, Paul M Holloway1, Janice Russell1, Mauro Perretti1, D Neil Granger1, Felicity N E Gavins2. 1. From Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center-Shreveport (S.A.V., P.M.H., J.R., D.N.G., F.N.E.G.); Department for General and Visceral Surgery, University Hospital Muenster, Germany (F.B.); William Harvey Research Institute, Queen Mary University of London, UK (M.P.); and Division of Brain Sciences, Imperial College London, UK (F.N.E.G.). 2. From Department of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center-Shreveport (S.A.V., P.M.H., J.R., D.N.G., F.N.E.G.); Department for General and Visceral Surgery, University Hospital Muenster, Germany (F.B.); William Harvey Research Institute, Queen Mary University of London, UK (M.P.); and Division of Brain Sciences, Imperial College London, UK (F.N.E.G.). fgavin@lsuhsc.edu.
Abstract
BACKGROUND: Platelet activation at sites of vascular injury is essential for hemostasis, but it is also a major pathomechanism underlying ischemic injury. Because anti-inflammatory therapies limit thrombosis and antithrombotic therapies reduce vascular inflammation, we tested the therapeutic potential of 2 proresolving endogenous mediators, annexin A1 N-terminal derived peptide (AnxA1Ac2-26) and aspirin-triggered lipoxin A4 (15-epi-lipoxin A4), on the cerebral microcirculation after ischemia/reperfusion injury. Furthermore, we tested whether the lipoxin A4 receptor formyl-peptide receptor 2/3 (Fpr2/3; ortholog to human FPR2/lipoxin A4 receptor) evoked neuroprotective functions after cerebral ischemia/reperfusion injury. METHODS AND RESULTS: Using intravital microscopy, we found that cerebral ischemia/reperfusion injury was accompanied by neutrophil and platelet activation and neutrophil-platelet aggregate formation within cerebral microvessels. Moreover, aspirin-triggered lipoxin A4 activation of neutrophil Fpr2/3 regulated neutrophil-platelet aggregate formation in the brain and inhibited the reactivity of the cerebral microvasculature. The same results were obtained with AnxA1Ac2-26 administration. Blocking Fpr2/lipoxin A4 receptor with the antagonist Boc2 reversed this effect, and treatments were ineffective in Fpr2/3 knockout mice, which displayed an exacerbated disease severity, evidenced by increased infarct area, blood-brain barrier dysfunction, increased neurological score, and elevated levels of cytokines. Furthermore, aspirin treatment significantly reduced cerebral leukocyte recruitment and increased endogenous levels of aspirin-triggered lipoxin A4, effects again mediated by Fpr2/3. CONCLUSION: Fpr2/lipoxin A4 receptor is a therapeutic target for initiating endogenous proresolving, anti-inflammatory pathways after cerebral ischemia/reperfusion injury.
BACKGROUND: Platelet activation at sites of vascular injury is essential for hemostasis, but it is also a major pathomechanism underlying ischemic injury. Because anti-inflammatory therapies limit thrombosis and antithrombotic therapies reduce vascular inflammation, we tested the therapeutic potential of 2 proresolving endogenous mediators, annexin A1 N-terminal derived peptide (AnxA1Ac2-26) and aspirin-triggered lipoxin A4 (15-epi-lipoxin A4), on the cerebral microcirculation after ischemia/reperfusion injury. Furthermore, we tested whether the lipoxin A4 receptorformyl-peptide receptor 2/3 (Fpr2/3; ortholog to humanFPR2/lipoxin A4 receptor) evoked neuroprotective functions after cerebral ischemia/reperfusion injury. METHODS AND RESULTS: Using intravital microscopy, we found that cerebral ischemia/reperfusion injury was accompanied by neutrophil and platelet activation and neutrophil-platelet aggregate formation within cerebral microvessels. Moreover, aspirin-triggered lipoxin A4 activation of neutrophil Fpr2/3 regulated neutrophil-platelet aggregate formation in the brain and inhibited the reactivity of the cerebral microvasculature. The same results were obtained with AnxA1Ac2-26 administration. Blocking Fpr2/lipoxin A4 receptor with the antagonist Boc2 reversed this effect, and treatments were ineffective in Fpr2/3 knockout mice, which displayed an exacerbated disease severity, evidenced by increased infarct area, blood-brain barrier dysfunction, increased neurological score, and elevated levels of cytokines. Furthermore, aspirin treatment significantly reduced cerebral leukocyte recruitment and increased endogenous levels of aspirin-triggered lipoxin A4, effects again mediated by Fpr2/3. CONCLUSION:Fpr2/lipoxin A4 receptor is a therapeutic target for initiating endogenous proresolving, anti-inflammatory pathways after cerebral ischemia/reperfusion injury.
Authors: U Waje-Andreassen; J Kråkenes; E Ulvestad; L Thomassen; K-M Myhr; J Aarseth; C A Vedeler Journal: Acta Neurol Scand Date: 2005-06 Impact factor: 3.209
Authors: P G Trentin; T P T Ferreira; A C S Arantes; B T Ciambarella; R S B Cordeiro; R J Flower; M Perretti; M A Martins; P M R Silva Journal: Br J Pharmacol Date: 2015-04-10 Impact factor: 8.739
Authors: Keqiang Chen; Pablo Iribarren; Jian Huang; Lingzhi Zhang; Wanghua Gong; Edward H Cho; Stephen Lockett; Nancy M Dunlop; Ji Ming Wang Journal: J Immunol Date: 2007-02-01 Impact factor: 5.422
Authors: Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy Journal: Pharmacol Rev Date: 2009-06-04 Impact factor: 25.468
Authors: Tamara Boltersdorf; Junaid Ansari; Elena Y Senchenkova; Jieny Groeper; Denise Pajonczyk; Shantel A Vital; Gaganpreet Kaur; J Steve Alexander; Thomas Vogl; Ursula Rescher; Nicholas J Long; Felicity N E Gavins Journal: Theranostics Date: 2020-05-17 Impact factor: 11.556
Authors: Helen K Smith; Seiichi Omura; Shantel A Vital; Felix Becker; Elena Y Senchenkova; Gaganpreet Kaur; Ikuo Tsunoda; Shayn M Peirce; Felicity N E Gavins Journal: FASEB J Date: 2017-12-21 Impact factor: 5.191
Authors: Felix Becker; Emily Romero; Jason Goetzmann; Dana L Hasselschwert; Beth Dray; John Vanchiere; Jane Fontenot; J Winny Yun; Paul C Norris; Luke White; Melany Musso; Charles N Serhan; J Steven Alexander; Felicity N E Gavins Journal: Am J Pathol Date: 2019-10 Impact factor: 4.307
Authors: Brian E Sansbury; Xiaofeng Li; Blenda Wong; Andreas Patsalos; Nikolas Giannakis; Michael J Zhang; Laszlo Nagy; Matthew Spite Journal: Proc Natl Acad Sci U S A Date: 2020-06-08 Impact factor: 11.205